JP2018533376A - 赤血球系譜を冒す代謝疾患に罹患している被験体から単離された細胞の遺伝子編集の方法、上記方法により得られた細胞、及びそれらの使用 - Google Patents
赤血球系譜を冒す代謝疾患に罹患している被験体から単離された細胞の遺伝子編集の方法、上記方法により得られた細胞、及びそれらの使用 Download PDFInfo
- Publication number
- JP2018533376A JP2018533376A JP2018543439A JP2018543439A JP2018533376A JP 2018533376 A JP2018533376 A JP 2018533376A JP 2018543439 A JP2018543439 A JP 2018543439A JP 2018543439 A JP2018543439 A JP 2018543439A JP 2018533376 A JP2018533376 A JP 2018533376A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- gene
- pklr
- cell
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000925 erythroid effect Effects 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 41
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 25
- 208000016097 disease of metabolism Diseases 0.000 title claims description 13
- 230000002068 genetic effect Effects 0.000 title claims description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 154
- 238000010362 genome editing Methods 0.000 claims abstract description 65
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims abstract description 58
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 48
- 101150025052 Pklr gene Proteins 0.000 claims abstract description 42
- 230000003394 haemopoietic effect Effects 0.000 claims abstract description 41
- 230000008672 reprogramming Effects 0.000 claims abstract description 33
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 31
- 238000012937 correction Methods 0.000 claims abstract description 6
- 101001091536 Homo sapiens Pyruvate kinase PKLR Proteins 0.000 claims description 91
- 102100034909 Pyruvate kinase PKLR Human genes 0.000 claims description 89
- 238000010459 TALEN Methods 0.000 claims description 81
- 239000011159 matrix material Substances 0.000 claims description 61
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 52
- 238000002744 homologous recombination Methods 0.000 claims description 46
- 230000006801 homologous recombination Effects 0.000 claims description 46
- 108020004999 messenger RNA Proteins 0.000 claims description 43
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 42
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 230000036961 partial effect Effects 0.000 claims description 29
- 230000035772 mutation Effects 0.000 claims description 28
- 101710163270 Nuclease Proteins 0.000 claims description 22
- 229950010131 puromycin Drugs 0.000 claims description 21
- 210000000130 stem cell Anatomy 0.000 claims description 20
- 108020004705 Codon Proteins 0.000 claims description 15
- 210000001185 bone marrow Anatomy 0.000 claims description 15
- 239000002609 medium Substances 0.000 claims description 15
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 14
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 14
- 102000036693 Thrombopoietin Human genes 0.000 claims description 13
- 108010041111 Thrombopoietin Proteins 0.000 claims description 13
- 102000000646 Interleukin-3 Human genes 0.000 claims description 12
- 108010002386 Interleukin-3 Proteins 0.000 claims description 12
- 230000035755 proliferation Effects 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 11
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 238000012423 maintenance Methods 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims description 9
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 claims description 9
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 claims description 9
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims description 9
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 8
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 claims description 7
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 7
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 claims description 7
- 102100020677 Krueppel-like factor 4 Human genes 0.000 claims description 7
- 241000711408 Murine respirovirus Species 0.000 claims description 6
- 238000010361 transduction Methods 0.000 claims description 6
- 230000026683 transduction Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
- 210000003714 granulocyte Anatomy 0.000 claims description 4
- -1 stem cell factor Proteins 0.000 claims description 4
- 229940104230 thymidine Drugs 0.000 claims description 4
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 3
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims 2
- 238000005457 optimization Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000013459 approach Methods 0.000 abstract description 11
- 108020005115 Pyruvate Kinase Proteins 0.000 description 42
- 102000013009 Pyruvate Kinase Human genes 0.000 description 36
- 108700028369 Alleles Proteins 0.000 description 30
- 210000000267 erythroid cell Anatomy 0.000 description 25
- 230000004069 differentiation Effects 0.000 description 24
- 239000002299 complementary DNA Substances 0.000 description 22
- 201000008542 polycystic kidney disease 2 Diseases 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 16
- 238000007857 nested PCR Methods 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 13
- 230000010354 integration Effects 0.000 description 13
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 12
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000001332 colony forming effect Effects 0.000 description 12
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 11
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 11
- 102000006601 Thymidine Kinase Human genes 0.000 description 11
- 108020004440 Thymidine kinase Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 229940076264 interleukin-3 Drugs 0.000 description 10
- 208000030151 polycystic kidney disease 3 with or without polycystic liver disease Diseases 0.000 description 10
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 108700014844 flt3 ligand Proteins 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 210000000066 myeloid cell Anatomy 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 7
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 7
- 108020005345 3' Untranslated Regions Proteins 0.000 description 6
- 102000003951 Erythropoietin Human genes 0.000 description 6
- 108090000394 Erythropoietin Proteins 0.000 description 6
- 206010043276 Teratoma Diseases 0.000 description 6
- 229940105423 erythropoietin Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000132536 Cirsium Species 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000007480 sanger sequencing Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000037442 genomic alteration Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 210000003013 erythroid precursor cell Anatomy 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000003924 normoblast Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000007482 whole exome sequencing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102100021592 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000002960 bfu-e Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102100028734 1,4-alpha-glucan-branching enzyme Human genes 0.000 description 1
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- GXIURPTVHJPJLF-UWTATZPHSA-N 2-phosphoglycerate Natural products OC[C@H](C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UWTATZPHSA-N 0.000 description 1
- GXIURPTVHJPJLF-UHFFFAOYSA-N 2-phosphoglyceric acid Chemical compound OCC(C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 101150101112 7 gene Proteins 0.000 description 1
- 101150106774 9 gene Proteins 0.000 description 1
- 102100024053 AP-4 complex accessory subunit RUSC2 Human genes 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102100040280 Acyl-protein thioesterase 1 Human genes 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 244000101724 Apium graveolens Dulce Group Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 108010061118 Apolipoprotein A-V Proteins 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 101000693922 Bos taurus Albumin Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 102100024117 Disks large homolog 2 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101710191461 F420-dependent glucose-6-phosphate dehydrogenase Proteins 0.000 description 1
- 101150081880 FGF1 gene Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102100035716 Glycophorin-A Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 102100030826 Hemoglobin subunit epsilon Human genes 0.000 description 1
- 108091005879 Hemoglobin subunit epsilon Proteins 0.000 description 1
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 description 1
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001058479 Homo sapiens 1,4-alpha-glucan-branching enzyme Proteins 0.000 description 1
- 101000690059 Homo sapiens AP-4 complex accessory subunit RUSC2 Proteins 0.000 description 1
- 101001038518 Homo sapiens Acyl-protein thioesterase 1 Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101001053980 Homo sapiens Disks large homolog 2 Proteins 0.000 description 1
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000590691 Homo sapiens MAGUK p55 subfamily member 2 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000594467 Homo sapiens Olfactory receptor 2T11 Proteins 0.000 description 1
- 101000594469 Homo sapiens Olfactory receptor 2T27 Proteins 0.000 description 1
- 101000594473 Homo sapiens Olfactory receptor 2T35 Proteins 0.000 description 1
- 101001096178 Homo sapiens Pleckstrin homology domain-containing family A member 5 Proteins 0.000 description 1
- 101000650694 Homo sapiens Roundabout homolog 1 Proteins 0.000 description 1
- 101000600912 Homo sapiens Substance-K receptor Proteins 0.000 description 1
- 101000835720 Homo sapiens Transcription elongation factor A protein 1 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000833157 Homo sapiens Zinc finger protein AEBP2 Proteins 0.000 description 1
- 101000691578 Homo sapiens Zinc finger protein PLAG1 Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102100035497 Olfactory receptor 2T11 Human genes 0.000 description 1
- 102100035499 Olfactory receptor 2T27 Human genes 0.000 description 1
- 102100035496 Olfactory receptor 2T35 Human genes 0.000 description 1
- 108050002069 Olfactory receptors Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102100037866 Pleckstrin homology domain-containing family A member 5 Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000030118 Red blood cell disease Diseases 0.000 description 1
- 102100027702 Roundabout homolog 1 Human genes 0.000 description 1
- 102100037342 Substance-K receptor Human genes 0.000 description 1
- 238000012245 TALEN-based genome engineering Methods 0.000 description 1
- 101150002347 TCEA1 gene Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102100026430 Transcription elongation factor A protein 1 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 102100024389 Zinc finger protein AEBP2 Human genes 0.000 description 1
- 102100026200 Zinc finger protein PLAG1 Human genes 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 208000022806 beta-thalassemia major Diseases 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008668 cellular reprogramming Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 208000019501 erythrocyte disease Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000055276 human IL3 Human genes 0.000 description 1
- 102000055151 human KITLG Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000009438 off-target cleavage Effects 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 101150035777 sev gene Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2311—Interleukin-11 (IL-11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
a. 哺乳動物被験体、好ましくはヒト被験体から単離された末梢血単核細胞を培養し、そしてこれらの細胞を、SCF、TPO、FLT3L、顆粒球コロニー刺激因子(G−CSF)及びIL−3の存在下で、好ましくは少なくとも4日間にわたり増殖させることで、造血始原体及び骨髄委任細胞の維持及び増殖を促進する工程と、
b. 上記工程a)から得られた細胞を、好ましくは以下の4種のリプログラミング因子:OCT3/4、KLF4、SOX2及びc−MYCをコードするセンダイウイルスベクタープラットフォーム(SeV)を使用した形質導入プロトコルを使用することによってリプログラムし、そしてこれらの細胞を、好ましくは同じ培地中で好ましくは3日間から6日間まで維持する工程と、
c. 任意に、上記細胞を回収する工程と、
を含む、方法に関する。
d. 内因性の1番目のエキソン及び部分的なcDNAによって形成されるキメラ型mRNAを内因性プロモーターの制御下で発現するように、部分的なcDNAが標的遺伝子の或る座位中に挿入されるノックイン方略を介した、好ましくは相同組換え(HR)を促進するためにヌクレアーゼが使用される遺伝子編集により、人工多能性幹細胞において存在する代謝疾患を引き起こす遺伝子中の1つ以上の突然変異を修正する工程と、
e. 任意に、上記ノックイン細胞を回収する工程と、
を更に含む。
d. スプライスアクセプターシグナルを先頭に有するエキソン3からエキソン11にまたがる部分的なコドン最適化(cDNA)RPK遺伝子を含み、これらの要素の両端にPKLR遺伝子の標的座位中の配列と一致する2つのホモロジーアームを有する治療マトリクスを使用することによるノックイン方略を介した、好ましくはHRを促進するためにヌクレアーゼが使用されるPKLR遺伝子の遺伝子編集により、人工多能性幹細胞において存在するPKLR遺伝子中の1つ以上の突然変異を修正し、このマトリクスが相同組換えによりPKLR遺伝子の標的座位中に導入される工程と、
e. 任意に、上記ノックイン細胞を回収する工程と、
を更に含む。
d. スプライスアクセプターシグナルを先頭に有するエキソン3からエキソン11にまたがる部分的なコドン最適化(cDNA)RPK遺伝子を含み、これらの要素の両端にPKLR遺伝子の2番目のイントロン中の配列と一致する2つのホモロジーアームを有する治療マトリクスを使用することによるノックイン方略を介した、好ましくはHRを促進するためにヌクレアーゼが使用されるPKLR遺伝子の遺伝子編集により、人工多能性幹細胞において存在するPKLR遺伝子中の1つ以上の突然変異を修正し、このマトリクスが相同組換えによりPKLR遺伝子の2番目のイントロン中に導入される工程と、
e. 任意に、上記ノックイン細胞を回収する工程と、
を更に含む。
ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATTACCCATACGATGTTCCAGATTACGCTATCGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGATCAAACCGAAGGTTCGTTCGACAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACACACGCGCACATCGTTGCGTTAAGCCAACACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACATGATCGCAGCGTTGCCAGAGGCGACACACGAAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTCTGGAGGCCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCGTGACCGCAGTGGAGGCAGTGCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCTCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGCGGCAGGCCGGCGCTGGAGAGCATTGTTGCCCAGTTATCTCGCCCTGATCCGGCGTTGGCCGCGTTGACCAACGACCACCTCGTCGCCTTGGCCTGCCTCGGCGGGCGTCCTGCGCTGGATGCAGTGAAAAAGGGATTGGGGGATCCTATCAGCCGTTCCCAGCTGGTGAAGTCCGAGCTGGAGGAGAAGAAATCCGAGTTGAGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCGGAACAGCACCCAGGACCGTATCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGCAAGCACCTGGGCGGCTCCAGGAAGCCCGACGGCGCCATCTACACCGTGGGCTCCCCCATCGACTACGGCGTGATCGTGGACACCAAGGCCTACTCCGGCGGCTACAACCTGCCCATCGGCCAGGCCGACGAAATGCAGAGGTACGTGGAGGAGAACCAGACCAGGAACAAGCACATCAACCCCAACGAGTGGTGGAAGGTGTACCCCTCCAGCGTGACCGAGTTCAAGTTCCTGTTCGTGTCCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCTGAACCACATCACCAACTGCAACGGCGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGATCAAGGCCGGCACCCTGACCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCGGCCGACTGATAA。
ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATAAGGAGACCGCCGCTGCCAAGTTCGAGAGACAGCACATGGACAGCATCGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGATCAAACCGAAGGTTCGTTCGACAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACACACGCGCACATCGTTGCGTTAAGCCAACACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACATGATCGCAGCGTTGCCAGAGGCGACACACGAAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTCTGGAGGCCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCGTGACCGCAGTGGAGGCAGTGCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCTCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGCGGCAGGCCGGCGCTGGAGAGCATTGTTGCCCAGTTATCTCGCCCTGATCCGGCGTTGGCCGCGTTGACCAACGACCACCTCGTCGCCTTGGCCTGCCTCGGCGGGCGTCCTGCGCTGGATGCAGTGAAAAAGGGATTGGGGGATCCTATCAGCCGTTCCCAGCTGGTGAAGTCCGAGCTGGAGGAGAAGAAATCCGAGTTGAGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCGGAACAGCACCCAGGACCGTATCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGCAAGCACCTGGGCGGCTCCAGGAAGCCCGACGGCGCCATCTACACCGTGGGCTCCCCCATCGACTACGGCGTGATCGTGGACACCAAGGCCTACTCCGGCGGCTACAACCTGCCCATCGGCCAGGCCGACGAAATGCAGAGGTACGTGGAGGAGAACCAGACCAGGAACAAGCACATCAACCCCAACGAGTGGTGGAAGGTGTACCCCTCCAGCGTGACCGAGTTCAAGTTCCTGTTCGTGTCCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCTGAACCACATCACCAACTGCAACGGCGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGATCAAGGCCGGCACCCTGACCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCGGCCGACTGATAA。
GCCCTGCCAGCAGAAGCGTGGAGCGGCTGAAAGAGATGATCAAGGCCGGCATGAATATCGCCCGGCTGAACTTCTCCCACGGCAGCCACGAGTACCACGCAGAGAGCATTGCCAACGTCCGGGAGGCCGTGGAGAGCTTTGCCGGCAGCCCCCTGAGCTACAGACCCGTGGCCATTGCCCTGGACACCAAGGGCCCCGAGATCAGAACAGGAATTCTGCAGGGAGGGCCTGAGAGCGAGGTGGAGCTGGTGAAGGGCAGCCAAGTGCTGGTGACCGTGGACCCCGCCTTCAGAACCAGAGGCAACGCCAACACAGTGTGGGTGGACTACCCCAACATCGTGCGGGTGGTGCCTGTGGGCGGCAGAATCTACATCGACGACGGCCTGATCAGCCTGGTGGTGCAGAAGATCGGACCTGAGGGCCTGGTGACCCAGGTCGAGAATGGCGGCGTGCTGGGCAGCAGAAAGGGCGTGAATCTGCCAGGCGCCCAGGTGGACCTGCCTGGCCTGTCTGAGCAGGACGTGAGAGACCTGAGATTTGGCGTGGAGCACGGCGTGGACATCGTGTTCGCCAGCTTCGTGCGGAAGGCCTCTGATGTGGCCGCCGTGAGAGCCGCTCTGGGCCCTGAAGGCCACGGCATCAAGATCATCAGCAAGATCGAGAACCACGAGGGCGTGAAGCGGTTCGACGAGATCCTGGAAGTGTCCGACGGCATCATGGTGGCCAGAGGCGACCTGGGCATCGAGATCCCCGCCGAGAAGGTGTTCCTGGCCCAGAAAATGATGATCGGACGGTGCAACCTGGCCGGCAAACCTGTGGTGTGCGCCACCCAGATGCTGGAAAGCATGATCACCAAGCCCAGACCCACCAGAGCCGAGACAAGCGACGTGGCCAACGCCGTGCTGGATGGCGCTGACTGCATCATGCTGTCCGGCGAGACAGCCAAGGGCAACTTCCCCGTGGAGGCCGTGAAGATGCAGCACGCCATTGCCAGAGAAGCCGAGGCCGCCGTGTACCACCGGCAGCTGTTCGAGGAACTGCGGAGAGCCGCCCCTCTGAGCAGAGATCCCACCGAAGTGACCGCCATCGGAGCCGTGGAAGCCGCCTTCAAGTGCTGCGCCGCTGCAATCATCGTGCTGACCACCACAGGCAGAAGCGCCCAGCTGCTGTCCAGATACAGACCCAGAGCCGCCGTGATCGCCGTGACAAGATCCGCCCAGGCCGCTAGACAGGTCCACCTGTGCAGAGGCGTGTTCCCCCTGCTGTACCGGGAGCCTCCCGAGGCCATCTGGGCCGACGACGTGGACAGACGGGTGCAGTTCGGCATCGAGAGCGGCAAGCTGCGGGGCTTCCTGAGAGTGGGCGACCTGGTGATCGTGGTGACAGGCTGGCGGCCTGGCAGCGGCTACACCAACATCATGAGGGTGCTGTCCATCAGC。
CCGGGTAGGGGAGGCGCTTTTCCCAAGGCAGTCTGGAGCATGCGCTTTAGCAGCCCCGCTGGGCACTTGGCGCTACACAAGTGGCCTCTGGCCTCGCACACATTCCACATCCACCGGTAGGCGCCAACCGGCTCCGTTCTTTGGTGGCCCCTTCGCGCCACCTTCTACTCCTCCCCTAGTCAGGAAGTTCCCCCCCGCCCCGCAGCTCGCGTCGTGCAGGACGTGACAAATGGAAGTAGCACGTCTCACTAGTCTCGTGCAGATGGACAGCACCGCTGAGCAATGGAAGCGGGTAGGCCTTTGGGGCAGCGGCCAATAGCAGCTTTGCTCCTTCGCTTTCTGGGCTCAGAGGCTGGGAAGGGGTGGGTCCGGGGGCGGGCTCAGGGGCGGGCTCAGGGGCGGGGCGGGCGCCCGAAGGTCCTCCGGAGGCCCGGCATTCTGCACGCTTCAAAAGCGCACGTCTGCCGCGCTGTTCTCCTCTTCCTCATCTCCGGGCCTTTCGACCGATCATCAAGCTTGATCCTCATGACCGAGTACAAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCGGGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTCCTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCGCCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTGCCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCGGATCCATGCCCACGCTACTGCGGGTTTATATAGACGGTCCCCACGGGATGGGGAAAACCACCACCACGCAACTGCTGGTGGCCCTGGGTTCGCGCGACGATATCGTCTACGTACCCGAGCCGATGACTTACTGGCGGGTGCTGGGGGCTTCCGAGACAATCGCGAACATCTACACCACACAACACCGCCTCGACCAGGGTGAGATATCGGCCGGGGACGCGGCGGTGGTAATGACAAGCGCCCAGATAACAATGGGCATGCCTTATGCCGTGACCGACGCCGTTCTGGCTCCTCATATCGGGGGGGAGGCTGGGAGCTCACATGCCCCGCCCCCGGCCCTCACCCTCATCTTCGACCGCCATCCCATCGCCGCCCTCCTGTGCTACCCGGCCGCGCGGTACCTTATGGGCAGCATGACCCCCCAGGCCGTGCTGGCGTTCGTGGCCCTCATCCCGCCGACCTTGCCCGGCACCAACATCGTGCTTGGGGCCCTTCCGGAGGACAGACACATCGACCGCCTGGCCAAACGCCAGCGCCCCGGCGAGCGGCTGGACCTGGCTATGCTGGCTGCGATTCGCCGCGTTTACGGGCTACTTGCCAATACGGTGCGGTATCTGCAGTGCGGCGGGTCGTGGCGGGAGGACTGGGGACAGCTTTCGGGGACGGCCGTGCCGCCCCAGGGTGCCGAGCCCCAGAGCAACGCGGGCCCACGACCCCATATCGGGGACACGTTATTTACCCTGTTTCGGGCCCCCGAGTTGCTGGCCCCCAACGGCGACCTGTATAACGTGTTTGCCTGGGCCTTGGACGTCTTGGCCAAACGCCTCCGTTCCATGCACGTCTTTATCCTGGATTACGACCAATCGCCCGCCGGCTGCCGGGACGCCCTGCTGCAACTTACCTCCGGGATGGTCCAGACCCACGTCACCACCCCCGGCTCCATACCGACGATATGCGACCTGGCGCGCACGTTTGCCCGGGAGATGGGGGAGGCTAACTGAGCTCTAGAGCGGCCAGTGTCGCGGTATCGATGAGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCC。
GCGGCGGGCCAGTGTGGCCCAACTGACCCAGGAGCTGGGCACTGCCTTCTTCCAGCAGCAGCAGCTGCCAGCTGCTATGGCAGACACCTTCCTGGAACACCTCTGCCTACTGGACATTGACTCCGAGCCCGTGGCTGCTCGCAGTACCAGCATCATTGCCACCATCGGTAAGCACTCCCATCCCCCTGCAGCCACACAGGGCCTATTGGTATTTCTTGAGGTGCTTCTTCATCTTTTGTCTCCTTTGAGACTTCTCCATGTTTGACACAGTCATTCATTTAACAAAAATTTGTTGAGCATATAGTAGACAAGATTTTGGGCCCTGGGAGTAGATCAGTGAAAAAAACAGACAAAAATCCCTACCCTTGGGGAGCTGACAGTCTAGCTGAGTATGACAATAAATAGTAAGCACAATAAATTATTTAAAATAAGTAAATTATTTATTCCGTTAGAAAGTGAGGCCGGGCATGGTGGCTCATGCCTGTAATCGCAGCATGTTGGGAGGCCCAGGTGGGCAGATCACTTGAGGTCAGGAGTTCGAGACTAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAATTAGCCGGGCATGGTGGTGCGTGCCTGCAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCGGAGACTGTGGTGAGCCGAGATCACACCATTGCATTCCAGCCTGGGCAACAGGAGAAAAACTCCATCTCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGTGGGCTGGGCTCAGTGGCTCATGCCTGTAATCCCAGCACTTTAGGAGGCCAAGGTTGGCAGATCGCTTGAGCCCAGGAGTTTGAGACCAGTCTGGGTAAATGGCAAAACCCATCTCTACAAAAAATACAAAACTTAGTTGAGTGTGGTGGTGCATGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGTGGGAGGATCACTTAAGCCCAG。
GAGAGAAAGAAAGAAAGAAGGAAAGAAAGAAAGAAAGAGAGAGAGAAAGAAGGAAGGAAGGAAGGAGGGAGGGAGGGAGGGAAGGAAGGAAGGAAAGAAAGCAAGCAGGCAAGAAAGAAAGAAAGAAAAGAAAGAAGGAAGGAAGGAAGGAAGGAAAGAAAGAAAGAAAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGGAGTGAAAGTTGGCCGGGCATGGTGGCTCTTGCCTATAATCCCAGCACTTTGGGAGGCTGAGGCAGGTGGATCACCTGAGGTCAGGGGTCCGAGACCAGCCTGGCTAATGTGGTGAAACTCTGTTTCTACTAAAAATACAAAAAATTAGCCAGGCATGGTGGCATGTGCCTATAATCCCAGCTACTCGGGAGGCTGAGGCAGGGGAATCGCTTGAACCCGGGAGACAGAGATTGCAGTGAGCCAAGATCACGCCATTGCACTCCAGTTTGGGCAACAAGAGCGAAACTCTGTTTGTTTGTTTGTTTGTTTTTAAAAAAAGAAAAAAAAGCTGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAAAATTATCCGGGCATGGTGGTGCATGCCTGTAATCCCAGCTACTCAGGAGGCTAAGGCAGGAGAATTGCTTGAACCTGGGAGGCGGAGGTTGCGGTGAGCCAAGATCGTGCCATTGCACCCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAGGCCAGGCGTGGTGTTTCATGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGACTGATCACGAGGTCAAGAGATCGATACCATCCTGGCCAACATG。
最初に、非組み込み型SeVによりiPSCへとリプログラムされるべき細胞源としてのPB−MNCの潜在的使用を評価するために、本発明者らは、これらの細胞のSeVへの感受性を分析した。PB−MNCを、特定のサイトカイン(幹細胞因子[SCF]、トロンボポエチン[TPO]、FLT3L、顆粒球コロニー刺激因子[G−CSF]及びIL−3)の存在下で4日間にわたり増殖させることで、造血始原体及び骨髄委任細胞の維持及び増殖を促進した。次いで、細胞に、アザミグリーン蛍光マーカーをコードするSeVを感染させた。5日後に、造血始原細胞(CD34陽性)、骨髄球系細胞(CD14陽性/CD15陽性)及びリンパ球系T細胞(CD3陽性)及びB細胞(CD19陽性)の形質導入を、フローサイトメトリーによって評価した。培養物中の大部分の細胞がTリンパ球系マーカー又はBリンパ球系マーカーを発現したが、それらのより低い割合(T細胞のうち10%、B細胞のうち3%)が、アザミグリーンを発現した。それに対して、培養物中に存在する骨髄球系細胞のうち54%及び造血始原体のうち76%は、上記蛍光マーカーについて陽性であり(データは示していない)、これは、SeVが、これらの培養条件下で、より少ない数の造血始原体及び骨髄球系細胞を優先的に形質導入することを裏付けている。
PKDiPSCの修正を達成するために、本発明者らは、FLAGタグ(配列番号6)に融合された、スプライスアクセプターシグナル(配列番号7)を先頭に有するエキソン3からエキソン11(配列番号5)にまたがる部分的なコドン最適化(cDNA)RPK遺伝子を含む治療マトリクスの挿入を基礎とするノックイン遺伝子編集方略を使用した。さらに、マウスホスホグリセリン酸キナーゼ(mPGK)プロモーターによって駆動されるピューロマイシン(Puro)耐性/チミジンキナーゼ(TK)融合遺伝子(配列番号8)を含む陽性−陰性選択カセットが、上記部分的な(cDNA)RPKの下流に含まれていた。これらの要素の両端には、PKLR遺伝子の2番目のイントロン中の配列に一致する2つのホモロジーアーム(配列番号9及び10)を有していた(図2A)。
サンガー法シーケンシングによる非標的アレルにおけるインデルの存在を評価するなかで、本発明者らは、PKD2iPSCにおけるPKLR TALEN切断部位から43塩基離れたところにg[2268A>G]のSNPの存在を確認した(図3A)。興味深いことに、全ての編集されたPKD2iPSCクローン(10個中10個)からの非標的アレルは、上述のSNPを有しており、それは、SNP変異体を有するアレルがHRを行うための妨げとなることを示唆している。さらに、どのPKD2iPSC編集クローンにおいても両アレルでの標的化は検出されなかった。それに対して、ホモロジーゲノム領域に一切SNPを有さない31個の編集されたPKD3iPSCクローンのうち3個は、両アレルで標的化された。
本発明者らは、リプログラミング及び遺伝子編集の全工程が、得られた細胞において遺伝的不安定性を誘導するかどうかを研究する必要があった。最初のアプローチとして、本発明者らは、種々のiPSC系統の核型分析を実施し、全ての場合において通常の核型を確認した。しかしながら、より明確な評価を有するために、本発明者らは、iPSC作製及び遺伝子編集修正を含む全ての工程を通して、比較ゲノムハイブリダイゼーション(CGH)及びエキソームシーケンシングによって遺伝的安定性を観察した。PKD2患者からのPB−MNC、リプログラムされたPKD2iPSC c58及び編集されたPKD2iPSC e11を、各々の工程の代表として選択した。これらの試料において、参照ゲノムDNAと比較した後に、コピー数多様性(CNV)が定義された。確認された全CNVのなかで、31個のCNVは、PKD2由来の当初のPB−MNC中に存在し、34個のCNVは、PKD2iPSC c78に検出され、そして32個のCNVは、PKD2iPSC e11中に検出された(表2)。PKD2iPSC c78において検出された23個のCNVは、既にPKD2のPB−MNC中に存在しており、それは、当初の患者試料のモザイク現象を示している。その一方で、PKD2iPSC c78及びPKD2iPSC e11に存在する4個のCNVだけは、一次試料中には検出されなかった。注目すべきことに、これらの4個のCNVは、ROBO1、GBE1、TCEA1、LYPLA1、DLG2、PLEKHA5、及びAEBP2等の遺伝子を含む染色体1q44、2p21、3p12.3−p12.1、及びXp11.22に存在した(表2)。
ノックイン組み込みを確認したら、遺伝子編集されたiPSCのPK表現型修正を評価した。本発明者らは、健康なドナーのiPSC系統(PB2iPSC c33)、両方の患者に由来するPKDのiPSC系統(PKD2iPSC c78及びPKD3iPSC c54)、及び相応の編集されたクローン(単一アレルで編集されたPKD2iPSC e11及びPKD3iPSC e88、並びに両アレルで標的化されたPKD3iPSC e31)からの種々のiPSC系統の赤血球系分化を誘導した。CD43、CD34、及びCD45等の特徴的な造血始原体マーカーが、時間の経過につれて現れ始め、同様の割合の細胞において発現された。赤血球系細胞は、その培養物中に明らかに観察され、そしてCD71抗原及びCD235a抗原の特定の赤血球系の組み合わせは、分化21日後に大部分の細胞に発現された(図4A)。さらに、分化31日目に分析された全てのiPSC系統に由来する細胞は、α−グロビン及びγ−グロビンが優勢で、β−グロビンが少量であり、残りは胚性ε−グロビン及びz−グロビンが検出される同様のグロビンパターンを示し、それは、これらの多能性系統の赤血球系分化を確証するものである。より重要なことには、3個のiPSC系統に由来する赤血球系細胞は、RPKを発現することが可能であった(図4B及び図4E)。編集された赤血球系細胞における近位遺伝子の発現の改変が、qRT−PCRによって確認されなかったことは注目すべきことである。
PKD患者及び健康なドナーからの末梢血を、通常の採血においてHospital Clinico Infantil Universitario Nino Jesus(スペイン、マドリード)、Centro Hospitalario de Coimbra(ポルトガル、コインブラ)、及びCIEMAT(スペイン、マドリード)の医療的ケアサービスから収集した。全ての試料は、同意書及び治験審査委員会の同意のもと収集した。PB−MNCを、Ficoll−Paque(GE Healthcare社)を使用して密度勾配によって単離した。PB−MNCを、StemSpan(STEMCELL Technologies社)において、100ng/mlのヒト幹細胞因子(SCF)、100ng/mlのhFLT3L、20ng/mlのhTPO、10ng/mlのG−CSF、及び2ng/mlのヒトIL−3(Peprotech社)を加えて4日間予備刺激した(図1A)。次いで、細胞を、OCT3/4、KLF4、SOX2、c−MYC、及びアザミグリーンを発現するDNAvec社(日本)寄贈のそれぞれ3のMOIのSeVのミックスで形質導入した。形質導入された細胞を、同じ培養培地中で更に4日間にわたり維持して、その後に、10ng/mlの塩基性の線維芽細胞成長因子(FGF)を供給した。形質導入から5日後に、細胞を回収し、ヒトES培地(knockout DMEM、20%のknockout血清代替品、1mMのL−グルタミン、及び1%の非必須アミノ酸[全てLife Technologies社製])、0.1mMのβ−メルカプトエタノール(Sigma-Aldrich社)、及び10ng/mlの塩基性のヒトFGF(Peprotech社)を有する照射されたヒト包皮線維芽細胞(HFF−1)がコートされた(ATCC)培養プレート上に播種した。ヒトES培地は、一日置きに交換した。ヒトES様コロニーが現れたら、それらのコロニーを、実体顕微鏡(Olympus社)下で選択し、そして各々のコロニーからのクローン培養物を樹立した。
iPSCを、Rockの阻害剤Y−27632(Sigma社)で処理してから、iPSCの単細胞懸濁液を、StemPro Accutase(Life Technologies社)処理によって作製し、次いで1.5mg又は5mgの各々のPKLR TALENサブユニットと一緒に4mgのHRマトリクスと一緒に又はHRマトリクス無しで、Amaxa Nucleofector(Lonza社)によりA23プログラムを使用してヌクレオフェクションした。ヌクレオフェクション後に、細胞を、照射されたPuroRマウス胚性線維芽細胞のフィーダー中にY−27632の存在下で播種し、そしてトランスフェクションから48時間後に、ピューロマイシン(0.5mg/ml)を、ヒトES培地に添加した。新たに形成されたPuroR−PKDiPSCコロニーを、6日間から10日間のピューロマイシン選択期間の間に個別にピックした。PuroR−PKDiPSCコロニーを、PCR及びサザンブロットにより増殖させて、分析することで、HRを検出した(図2B及び図2C)。
iPSC系統からの赤血球系分化は、特許された方法(国際公開第2014/013255号)を使用して実施した。簡潔には、本発明者らは、E.O.により開発された多段階のフィーダー不要のプロトコルを使用した。分化の前に、通常のiPSC、病気のiPSC、及び修正されたiPSCを、StemPro培地(Life Technologies社)中で、20ng/mlの塩基性のFGFを組換えビトロネクチン断片(Life Technologies社)の基質に添加して手動による継代を使用して維持した。分化の開始のために、胚様体(EB)を、BMP4、血管内皮増殖因子(VEGF)、Wnt3a、及びアクチビンAを含むStemline II培地(Sigma Aldrich社)中で形成した。第2工程において、造血分化を、FGFa、SCF、IGF2、TPO、及びヘパリンをEB因子に添加することによって誘導した。10日後に、造血始原体を採取し、赤血球系譜に沿った直接的な分化と、大規模な増殖の支持とのために、BMP4、SCF、Flt3リガンド、IL−3、IL−11、及びエリスロポエチン(EPO)を供給した新たなStemline II培地に再播種した。17日後に、細胞を、インスリン、トランスフェリン、SCF、IGF1、IL−3、IL−11、及びEPOを含むより特異的な赤血球系カクテルを含むStemline II培地中に7日間にわたり移した。7日間の最終成熟工程(24日目〜31日目)において、細胞を、インスリン、トランスフェリン、及びBSAを含み、EPOを補ったIMDM中に移した。細胞を、10日目、17日目、24日目、及び31日目に分析のために採取した。
ヒト造血始原体における本発明のノックイン遺伝子編集アプローチの適用の実現可能性を調査するために、iPSC遺伝子編集プロトコルを、造血始原体で実施するように適合させた。
PKLR座位におけるマトリクスの特異的な組み込みを、ネステッドPCRにより測定した。
第1のセット、KI F2(配列番号12:ACTGGGTGATTCTGGGTCTG)及びKI R2(配列番号13:GGGGAACTTCCTGACTAGGG)、並びに、
第2のセット、KI F3(配列番号14:GCTGCTGGGGACTAGACATC)及びKI R3(配列番号15:CGCCAAATCTCAGGTCTCTC)、
を要した。
ヌクレオフェクションされたDNAに関連する毒性を減らすために、mRNAとしてのPKLR TALENの使用を研究した。PKLR TALENのmRNAの安定性を改善するために、幾つかの修飾を導入することで、そのmRNA(配列番号4、β−グロビンの3’UTR)を安定化させるか、又は外因性mRNAに対する免疫応答を低減させた(配列番号3、VEEVの5’UTR、Hyde et al, Science 14 February 2014: 783-787を参照)。
遺伝子編集されたHSCの生着を、NSGマウスの骨髄において移植から4ヶ月後に、ヒト造血細胞(hCD45陽性)及びヒト造血始原体(CD45陽性/CD34陽性)の存在をFACSにより測定することによって評価した。
Aasen, T., Raya, A., Barrero, M.J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilic, J., Pekarik, V., Tiscornia, G., et al. (2008). Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 26, 1276-1284.
Abyzov, A., Mariani, J., Palejev, D., Zhang, Y., Haney, M.S., Tomasini, L., Ferrandino, A.F., Rosenberg Belmaker, L.A., Szekely, A., Wilson, M., et al. (2012). Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature 492, 438-442.
Amabile, G., Welner, R.S., Nombela-Arrieta, C., D’Alise, A.M., Di Ruscio, A., Ebralidze, A.K., Kraytsberg, Y., Ye, M., Kocher, O., Neuberg, D.S., et al. (2013). In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood 121, 1255-1264.
Asp, J., Persson, F., Kost-Alimova, M., and Stenman, G. (2006). CHCHD7-PLAG1 and TCEA1-PLAG1 gene fusions resulting from cryptic, intrachromosomal 8q rearrangements in pleomorphic salivary gland adenomas. Genes Chromosomes Cancer 45, 820-828.
Ban, H., Nishishita, N., Fusaki, N., Tabata, T., Saeki, K., Shikamura, M., Takada, N., Inoue, M., Hasegawa, M., Kawamata, S., and Nishikawa, S. (2011). Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad. Sci. USA 108, 14234-14239.
Beutler, E., and Gelbart, T. (2000). Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood 95, 3585-3588.
Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., Lahaye, T., Nickstadt, A., and Bonas, U. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509-1512.
Carroll, D. (2011). Genome engineering with zinc-finger nucleases. Genetics 188, 773-782.
Cavazza, A., Moiani, A., and Mavilio, F. (2013). Mechanisms of retroviral integration and mutagenesis. Hum. Gene Ther. 24, 119-131.
WellcomeTrust Sanger Institute (2014).COSMIC: catalog of somatic mutations in cancer. http://cancer.sanger.ac.uk/cancergenome/ projects/cosmic/.
De Gobbi, M., Viprakasit, V., Hughes, J.R., Fisher, C., Buckle, V.J., Ayyub, H., Gibbons, R.J., Vernimmen, D., Yoshinaga, Y., de Jong, P., et al. (2006). A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science 312, 1215-1217.
Deyle, D.R., Li, L.B., Ren, G., and Russell, D.W. (2014). The effects of polymorphisms on human gene targeting. Nucleic Acids Res. 42, 3119-3124.
Fermo, E., Bianchi, P., Chiarelli, L.R., Cotton, F., Vercellati, C., Writzl, K., Baker, K., Hann, I., Rodwell, R., Valentini, G., and Zanella, A. (2005). Red cell pyruvate kinase deficiency: 17 new mutations of the PK-LR gene. Br. J. Haematol. 129, 839-846.
Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., and Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 85, 348-362.
Garate, Z., Davis, B.R., Quintana-Bustamante, O., and Segovia, J.C. (2013). New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells. Hum. Gene Ther. 24, 571-583.
Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M.C., et al. (2014). Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510, 235-240.
Gore, A., Li, Z., Fung, H.L., Young, J.E., Agarwal, S., Antosiewicz- Bourget, J., Canto, I., Giorgetti, A., Israel, M.A., Kiskinis, E., et al. (2011). Somatic coding mutations in human induced pluripotent stem cells. Nature 471, 63-67.
Hussein, S.M., Batada, N.N., Vuoristo, S., Ching, R.W., Autio, R.,Na¨rva¨, E., Ng, S., Sourour, M., Ha¨ma¨la¨inen, R., Olsson, C., et al. (2011). Copy number variation and selection during reprogramming to pluripotency. Nature 471, 58-62.
Karakikes, I., Stillitano, F., Nonnenmacher, M., Tzimas, C., Sanoudou, D., Termglinchan, V., Kong, C.W., Rushing, S., Hansen, J., Ceholski, D., et al. (2015). Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat. Commun. 6, 6955.
Li J, Song W, Pan G, Zhou J.. “Advances in Understanding the Cell Types and Approaches Used for Generating Induced Pluripotent Stem Cells.” Journal of Hematology & Oncology 7 (2014): 50. PMC. Web. 7 Nov. 2016.
Loh, Y.H., Agarwal, S., Park, I.H., Urbach, A., Huo, H., Heffner, G.C., Kim, K., Miller, J.D., Ng, K., and Daley, G.Q. (2009). Generation of induced pluripotent stem cells from human blood. Blood 113, 5476-5479.
Lopez-Manzaneda S., Fananas S., Nieto-Romero V., Roman-Rodriguez F., Fernandez-Garcia M., Pino-Barrio M.J., Rodriguez-Fornes F., Diez-Cabezas B., Garcia-Bravo M., Navarro S., Quintana-Bustamante O.r and Segovia J.C; TITLE: Gene Editing in Adult Hematopoietic Stem Cells; JOURNAL/BOOK TITLE: In “Modern Tools for Genetic Engineering” Editor MSD Kormann. INTECH publishing 2016. ISBN: 978-953-51-4654-4.
Meza, N.W., Alonso-Ferrero, M.E., Navarro, S., Quintana-Bustamante, O., Valeri, A., Garcia-Gomez, M., Bueren, J.A., Bautista, J.M., and Segovia, J.C. (2009). Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme. Mol. Ther. 17, 2000-2009.
Nishimura, K., Sano, M., Ohtaka, M., Furuta, B., Umemura, Y., Nakajima, Y., Ikehara, Y., Kobayashi, T., Segawa, H., Takayasu, S., et al. (2011). Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J. Biol. Chem. 286, 4760-4771.
Nishishita, N., Takenaka, C., Fusaki, N., and Kawamata, S. (2011). Generation of human induced pluripotent stem cells from cord blood cells. J. Stem Cells 6, 101-108.
Park, I.H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A., Lerou, P.H., Lensch, M.W., and Daley, G.Q. (2008). Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141-146.
Porteus, M.H., and Carroll, D. (2005). Gene targeting using zinc finger nucleases. Nat. Biotechnol. 23, 967-973.
Renkawitz, J., Lademann, C.A., and Jentsch, S. (2014). Mechanisms and principles of homology search during recombination. Nat. Rev. Mol. Cell Biol. 15, 369-383.
Rio, P., Ban〜os, R., Lombardo, A., Quintana-Bustamante, O., Alvarez, L., Garate, Z., Genovese, P., Almarza, E., Valeri, A., D1´ez, B., et al. (2014). Targeted gene therapy and cell reprogramming in Fanconi anemia. EMBO Mol. Med. 6, 835-848.
Sebastiano, V., Maeder, M.L., Angstman, J.F., Haddad, B., Khayter, C., Yeo, D.T., Goodwin, M.J., Hawkins, J.S., Ramirez, C.L., Batista, L.F., et al. (2011). In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 29, 1717-1726.
Seki, T., Yuasa, S., Oda, M., Egashira, T., Yae, K., Kusumoto, D., Nakata, H., Tohyama, S., Hashimoto, H., Kodaira, M., et al. (2010). Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7, 11-14.
Song, B., Fan, Y., He,W., Zhu, D., Niu, X.,Wang, D., Ou, Z., Luo, M., and Sun, X. (2015). Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system. Stem Cells Dev. 24, 1053-1065.
Staerk, J., Dawlaty,M.M., Gao, Q., Maetzel, D., Hanna, J., Sommer, C.A., Mostoslavsky, G., and Jaenisch, R. (2010). Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 7, 20-24.
Suvatte, V., Tanphaichitr, V.S., Visuthisakchai, S., Mahasandana, C., Veerakul, G., Chongkolwatana, V., Chandanayingyong, D., and Issaragrisil, S. (1998). Bone marrow, peripheral blood and cord blood stem cell transplantation in children: ten years’ experience at Siriraj Hospital. Int. J. Hematol. 68, 411-419.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872.
Tanphaichitr, V.S., Suvatte, V., Issaragrisil, S., Mahasandana, C., Veerakul, G., Chongkolwatana, V., Waiyawuth, W., and Ideguchi, H. (2000). Successful bone marrow transplantation in a child with red blood cell pyruvate kinase deficiency. Bone Marrow Transplant. 26, 689-690.
Ye, Z., Zhan, H., Mali, P., Dowey, S., Williams, D.M., Jang, Y.Y., Dang, C.V., Spivak, J.L., Moliterno, A.R., and Cheng, L. (2009). Human- induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 114, 5473- 5480.
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920.
Zanella, A., Fermo, E., Bianchi, P., and Valentini, G. (2005). Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br. J. Haematol. 130, 11-25.
Zanella, A., Bianchi, P., and Fermo, E. (2007). Pyruvate kinase deficiency. Haematologica 92, 721-723.
Zou, J., Mali, P., Huang, X., Dowey, S.N., and Cheng, L. (2011). Sitespecific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118, 4599-4608.
Claims (23)
- 赤血球系譜を冒す代謝疾患に罹患している被験体から単離された細胞であって、前記細胞において存在する代謝疾患を引き起こす遺伝子中の1つ以上の突然変異が、内因性の1番目のエキソン及び部分的なcDNAによって形成されるキメラ型mRNAを内因性プロモーターの制御下で発現するように、部分的なcDNAが前記遺伝子の標的座位中に挿入されるノックイン方略を介した遺伝子編集により修正されており、かつ赤血球系譜へと分化する能力を有する、細胞。
- 前記細胞は、i)造血幹細胞若しくは始原細胞、又はii)成熟細胞から得られた人工多能性幹細胞、好ましくは末梢血単核細胞に由来する人工多能性幹細胞である、請求項1に記載の細胞。
- 前記代謝疾患は、ピルビン酸キナーゼ欠損症(PKD)である、請求項1又は2に記載の細胞。
- 前記遺伝子編集は、スプライスアクセプターシグナルを先頭に有するエキソン3からエキソン11にまたがる部分的なコドン最適化(cDNA)RPK遺伝子を含み、これらの要素の両端にPKLR遺伝子の標的座位中の配列と一致する2つのホモロジーアームを有する治療マトリクスを使用することによるノックイン方略を介して行われ、かつこのマトリクスは、相同組換えによりPKLR遺伝子の標的座位中に導入される、請求項3に記載の細胞。
- 前記標的座位は、PKLR遺伝子の2番目のイントロンである、請求項4に記載の細胞。
- 前記治療マトリクスは、ホスホグリセリン酸キナーゼプロモーターによって駆動されるピューロマイシン(Puro)耐性/チミジン(TK)融合遺伝子を好ましくは含む陽性−陰性選択カセットを更に含み、前記陽性−陰性選択カセットは、前記部分的なコドン最適化(cDNA)RPK遺伝子の下流に位置する、請求項4又は5に記載の細胞。
- 赤血球系譜を冒す代謝疾患に罹患している被験体から単離された細胞においてノックイン方略を介した遺伝子編集によって、前記細胞において存在する前記代謝疾患を引き起こす遺伝子中の1つ以上の突然変異を修正する方法であって、前記細胞は、前記赤血球系譜へと分化する能力を有し、かつ前記方法は、
内因性の1番目のエキソン及び部分的なcDNAによって形成されるキメラ型mRNAを内因性プロモーターの制御下で発現するように、部分的なcDNAが前記代謝疾患を引き起こす遺伝子の標的座位中に挿入されるノックイン方略を介した、好ましくは相同組換え(HR)を促進するために遺伝子特異的ヌクレアーゼが使用される遺伝子編集により、前記細胞において存在する前記代謝疾患を引き起こす遺伝子中の1つ以上の突然変異を修正する工程と、
任意に、前記ノックイン細胞を回収する工程と、
を含む、方法。 - 前記細胞は、i)造血幹細胞若しくは始原細胞、又はii)成熟細胞から得られた人工多能性幹細胞、好ましくは末梢血単核細胞に由来する人工多能性幹細胞である、請求項7に記載の方法。
- 前記細胞は、
a. 赤血球系譜を冒す代謝疾患に罹患している被験体から単離された末梢血単核細胞を細胞培養培地中で培養し、そしてこれらの細胞を、トロンボポエチン、FLT3L、幹細胞因子、顆粒球コロニー刺激因子(G−CSF)及びIL−3の存在下で、好ましくは少なくとも4日間にわたり増殖させることで、造血始原体及び骨髄委任細胞の維持及び増殖を促進する工程と、
b. 工程a)から得られた細胞を、以下の4種のリプログラミング因子:OCT3/4、KLF4、SOX2及びc−MYCをコードするセンダイウイルスベクタープラットフォーム(SeV)を使用することによる形質導入プロトコルによってリプログラムし、そしてこれらの細胞を、好ましくは同じ培地中で好ましくは3日間から6日間まで維持する工程と、
c. 任意に、前記細胞を回収する工程と、
を含む方法により末梢血単核細胞から得られる人工多能性幹細胞である、請求項8に記載の方法。 - 前記代謝疾患は、ピルビン酸キナーゼ欠損症(PKD)であり、前記遺伝子は、PKLR遺伝子であり、かつPKLR遺伝子は、スプライスアクセプターシグナルを先頭に有するエキソン3からエキソン11にまたがる部分的なコドン最適化(cDNA)RPK遺伝子を含み、これらの要素の両端にPKLR遺伝子の標的座位中の配列と一致する2つのホモロジーアームを有する治療マトリクスを使用することによるノックイン方略を介して、好ましくはHRを促進するために遺伝子特異的ヌクレアーゼを使用して遺伝子編集されており、このマトリクスは、相同組換え(HR)によりPKLR遺伝子の標的座位中に導入される、請求項7又は8に記載の方法。
- 前記標的座位は、PKLR遺伝子の2番目のイントロンである、請求項10に記載の方法。
- 前記ヌクレアーゼは、PKLR転写アクチベーター様エフェクターヌクレアーゼ(TALEN)であり、好ましくは、前記ヌクレアーゼは、配列番号1及び配列番号2によって規定される2つのサブユニットを含むPKLR TALENである、請求項10又は11に記載の方法。
- 前記ヌクレアーゼは、mRNAとして、好ましくは5’修飾及び/又は3’修飾を有するmRNAとして、より好ましくは、配列番号3が5’末端に付加されており、及び/又は配列番号4が3’末端に付加されているmRNAとして使用される、請求項10〜12のいずれか一項に記載の方法。
- 前記細胞は、
a. ピルビン酸キナーゼ欠損症(PKD)に罹患している被験体から単離された末梢血単核細胞を細胞培養培地中で培養し、そしてこれらの細胞を、トロンボポエチン、FLT3L、幹細胞因子、顆粒球コロニー刺激因子(G−CSF)及びIL−3の存在下で、好ましくは少なくとも4日間にわたり増殖させることで、造血始原体及び骨髄委任細胞の維持及び増殖を促進する工程と、
b. 工程a)から得られた細胞を、以下の4種のリプログラミング因子:OCT3/4、KLF4、SOX2及びc−MYCをコードするセンダイウイルスベクタープラットフォーム(SeV)を使用することによる形質導入プロトコルによってリプログラムし、そしてこれらの細胞を、好ましくは同じ培地中で好ましくは3日間から6日間まで維持する工程と、
c. 任意に、前記細胞を回収する工程と、
を含む方法により末梢血単核細胞から得られる人工多能性幹細胞である、請求項10〜13のいずれか一項に記載の方法。 - 請求項7〜9のいずれか一項に記載の方法により得られた又は得ることが可能な細胞。
- 請求項10〜14のいずれか一項に記載の方法により得られた又は得ることが可能な細胞。
- 療法において使用するための、請求項1〜6又は請求項15〜16のいずれか一項に記載の細胞。
- 赤血球系譜を冒す代謝疾患の治療において使用するための、請求項1〜2又は請求項15のいずれか一項に記載の細胞。
- ピルビン酸キナーゼ欠損症(PKD)の治療において使用するための、請求項3〜6又は請求項16のいずれか一項に記載の細胞。
- スプライスアクセプターシグナルを先頭に有するエキソン3からエキソン11にまたがる部分的なコドン最適化(cDNA)RPK遺伝子を含み、これらの要素の両端にPKLR遺伝子の標的座位中の配列と一致する2つのホモロジーアームを有する治療マトリクスであって、相同組換えによりPKLR遺伝子の標的座位中に、好ましくはPKLR遺伝子の2番目のイントロン中にそれ自体の導入が可能である、治療マトリクス。
- ホスホグリセリン酸キナーゼプロモーターによって駆動されるピューロマイシン(Puro)耐性/チミジン(TK)融合遺伝子を好ましくは含む陽性−陰性選択カセットを更に含み、前記陽性−陰性選択カセットは、前記部分的なコドン最適化(cDNA)RPKの下流に位置している、請求項20に記載の治療マトリクス。
- ピルビン酸キナーゼ欠損症(PKD)に罹患している被験者から単離された赤血球系譜の末梢血単核細胞に由来する人工多能性幹細胞において存在するPKLR遺伝子中の1つ以上の突然変異を、ノックイン方略を介して遺伝子編集することにより修正するための、請求項20又は21に記載の治療マトリクスのex vivo又はin vitroでの使用。
- 配列番号1により規定される左側のサブユニット及び配列番号2により規定される右側のサブユニットを含む、PKLR転写アクチベーター様エフェクターヌクレアーゼ(TALEN)。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382545 | 2015-11-05 | ||
EP15382545.0 | 2015-11-05 | ||
PCT/EP2016/076893 WO2017077135A1 (en) | 2015-11-05 | 2016-11-07 | Process of gene-editing of cells isolated from a subject suffering from a metabolic disease affecting the erythroid lineage, cells obtained by said process and uses thereof. |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018533376A true JP2018533376A (ja) | 2018-11-15 |
Family
ID=54601718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018543439A Pending JP2018533376A (ja) | 2015-11-05 | 2016-11-07 | 赤血球系譜を冒す代謝疾患に罹患している被験体から単離された細胞の遺伝子編集の方法、上記方法により得られた細胞、及びそれらの使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20180320138A1 (ja) |
EP (1) | EP3371300A1 (ja) |
JP (1) | JP2018533376A (ja) |
AU (1) | AU2016348782A1 (ja) |
CA (1) | CA3004171A1 (ja) |
WO (1) | WO2017077135A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108103027A (zh) * | 2018-02-02 | 2018-06-01 | 中国医学科学院血液病医院(血液学研究所) | 高效率血细胞重编程同时实现基因编辑的方法 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012333134B2 (en) | 2011-07-22 | 2017-05-25 | John Paul Guilinger | Evaluation and improvement of nuclease cleavage specificity |
MX370265B (es) * | 2012-05-25 | 2019-12-09 | Cellectis | Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia. |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
ES2615512B1 (es) | 2015-11-06 | 2018-03-15 | Universidad De Zaragoza | Dispositivo y sistema microfluídico para el estudio de cultivos celulares |
US11459560B2 (en) | 2015-11-23 | 2022-10-04 | The Regents Of The University Of Colorado | Methods and compositions for reprogramming cells |
ES2885833T3 (es) | 2016-04-20 | 2021-12-15 | Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P | Composición y métodos para potenciar la expresión génica de PKLR |
CA3032699A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
KR102687373B1 (ko) | 2017-03-23 | 2024-07-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
JP7403461B2 (ja) | 2017-10-16 | 2023-12-22 | セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー.エイ. エム.ピー. | ピルビン酸キナーゼ欠損症を治療するためのpklr送達用レンチウイルスベクター |
CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
WO2020191249A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6027721A (en) * | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
-
2016
- 2016-11-07 EP EP16794570.8A patent/EP3371300A1/en not_active Withdrawn
- 2016-11-07 JP JP2018543439A patent/JP2018533376A/ja active Pending
- 2016-11-07 CA CA3004171A patent/CA3004171A1/en not_active Abandoned
- 2016-11-07 US US15/773,960 patent/US20180320138A1/en not_active Abandoned
- 2016-11-07 WO PCT/EP2016/076893 patent/WO2017077135A1/en active Application Filing
- 2016-11-07 AU AU2016348782A patent/AU2016348782A1/en not_active Abandoned
Non-Patent Citations (5)
Title |
---|
BLOOD 2009 DEC 24;114(27):5473-80., JPN6021006993, ISSN: 0004454388 * |
BLOOD 2009 MAY 28;113(22):5476-9., JPN6021006992, ISSN: 0004454387 * |
O QUINTANA-BUSTAMANTE: "GENE EDITING OF THE PKLR LOCUS IN HUMAN HEMATOPOIETIC PROGENITORS BY TALE NUCLEASES", HUMAN GENE THERAPY, vol. 25, no. 11, JPN5018007693, November 2014 (2014-11-01), pages 2 - 67, XP055336677, ISSN: 0004454386 * |
O QUINTANA-BUSTAMANTE: "OPTIMIZATION OF GENE EDITING IN HUMAN HEMATOPOIETIC PROGENITORS TO INSERT A THERAPEUTIC 以下備考", HUMAN GENE THERAPY, vol. VOL: 26, NR: 10, JPN5018007691, October 2015 (2015-10-01), pages 28 - 29, ISSN: 0004454385 * |
PLOS ONE 2012;7(6):E38389, JPN6021006994, ISSN: 0004454389 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108103027A (zh) * | 2018-02-02 | 2018-06-01 | 中国医学科学院血液病医院(血液学研究所) | 高效率血细胞重编程同时实现基因编辑的方法 |
Also Published As
Publication number | Publication date |
---|---|
CA3004171A1 (en) | 2017-05-11 |
AU2016348782A1 (en) | 2018-05-31 |
EP3371300A1 (en) | 2018-09-12 |
WO2017077135A1 (en) | 2017-05-11 |
US20180320138A1 (en) | 2018-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018533376A (ja) | 赤血球系譜を冒す代謝疾患に罹患している被験体から単離された細胞の遺伝子編集の方法、上記方法により得られた細胞、及びそれらの使用 | |
US20240117380A1 (en) | Crispr/cas9 complex for genomic editing | |
CN108368520B (zh) | 多能细胞的基因组工程改造 | |
Xie et al. | Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac | |
Chang et al. | Modeling human severe combined immunodeficiency and correction by CRISPR/Cas9-enhanced gene targeting | |
JP2021106611A (ja) | ヌクレアーゼ介在性遺伝子発現調節 | |
Garate et al. | Generation of a high number of healthy erythroid cells from gene-edited pyruvate kinase deficiency patient-specific induced pluripotent stem cells | |
JP2017517256A (ja) | 遺伝子配列を編集する方法 | |
US20220033856A1 (en) | Methods for increasing fetal hemoglobin content in eukaryotic cells and uses thereof for the treatment of hemoglobinopathies | |
Antoniou et al. | Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression | |
Hong et al. | Rhesus iPSC safe harbor gene-editing platform for stable expression of transgenes in differentiated cells of all germ layers | |
Rahman et al. | Rescue of DNA-PK signaling and T-cell differentiation by targeted genome editing in a prkdc deficient iPSC disease model | |
Dolatshad et al. | Application of induced pluripotent stem cell technology for the investigation of hematological disorders | |
US20230158110A1 (en) | Gene editing of monogenic disorders in human hematopoietic stem cells -- correction of x-linked hyper-igm syndrome (xhim) | |
CN113316637A (zh) | 依靠人工反式激活物的选择 | |
Papapetrou | Gene and cell therapy for β-thalassemia and sickle cell disease with induced pluripotent stem cells (iPSCs): the next frontier | |
Guenechea et al. | Zita Garate, Oscar Quintana-Bustamante,* Ana M. Crane, 3 Emmanuel Olivier, 4 Laurent Poirot, 5 Roman Galetto, 5 Penelope Kosinski, 6 Collin Hill, 6 Charles Kung, 6 Xabi Agirre, 7 Israel Orman, Laura Cerrato, Omaira Alberquilla, Fatima Rodriguez-Fornes, Noemi Fusaki, 8 Felix Garcia-Sanchez, 9 Tabita M. Maia, 10 Maria L. Ribeiro, 10 Julian Sevilla, 11 Felipe Prosper, 7 Shengfang Jin, 6 Joanne Mountford, 4 | |
US20240318154A1 (en) | Gene therapy for the treatment of severe combined immunodeficiency (scid) related to rag1 | |
US20240010991A1 (en) | Materials and methods for bioengineered ipsc populations | |
Brendel et al. | Generation of X-CGD cells for vector evaluation from healthy donor CD34+ HSCs by shRNA-mediated knock down of gp91phox | |
WO2023015376A1 (en) | Mtor-targeted modification and uses thereof | |
WO2022243531A1 (en) | Gene therapy for the treatment of severe combined immunodeficiency (scid) related to rag1 | |
Firrito | Targeted Gene Correction and Reprogramming of SCID-X1 Fibroblasts to Rescue IL2RG Expression in iPSC-derived Hematopoietic Cells | |
WO2023144104A1 (en) | Base editing approaches for the treatment of βeta-thalassemia | |
Laskowski | Natural And Exogenous Genome Editing In Wiskott-Aldrich Syndrome Patient Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180628 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180628 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210302 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211026 |